| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H12FN3O3 |
| Molecular Weight | 313.2832 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O\C(=C/C(=O)C1=CC=C(CC2=CC=C(F)C=C2)O1)C3=NNC=N3
InChI
InChIKey=HFHDGHOGHWXXDT-ZSOIEALJSA-N
InChI=1S/C16H12FN3O3/c17-11-3-1-10(2-4-11)7-12-5-6-15(23-12)13(21)8-14(22)16-18-9-19-20-16/h1-6,8-9,22H,7H2,(H,18,19,20)/b14-8-
| Molecular Formula | C16H12FN3O3 |
| Molecular Weight | 313.2832 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
GW-810781 (wider known as S-1360) was initially developed by GlaxoSmithKline as HIV integrase inhibitor. GW-810781 was well-tolerated and showed acceptable pharmacokinetic profiles that is why it was studied in phase II clinical trials as a potential treatment for HIV infection. However, the development of the drug was discontinued in July 2003.
